Congress Will Not Tinker With FDA LDT Guidance Before Final, Staffers Indicate
This article was originally published in The Gray Sheet
Executive Summary
Both Democratic and Republican staffers on key congressional health committees say that members pushing forward a Senate “medical innovation” bill and backing “Cures” legislation in the House will not interfere with FDA’s proposed plan to regulate laboratory developed tests before the guidance is made final.